Atrogi Ab

Sigrid Therapeutics Ab

Zipforce Ab

Tore Bengtsson

Benjamin Pelcman

Alfonso E Garcia-Bennett

Robert Csikasz

Natalia Kupferschmidt

Møns Bengtsson

Eric Johnston

Muhammad Naeem Iqbal

Måns Bengtsson

There is provided herein a porous silica particle characterized by having a hierarchical pore structure wherein at least about 20% of the pores of the silica particle are of a size in the range of from about 7.0 to about 13.0 nm, and at least about 10% of the pores of the silica particle are of a size in the range of from about 0.5 to about 5.0 nm, and by having a particle size of from about 0.1 μm to about 10.0 μm. There is also provided compositions comprising such silica particles, process for their preparation, and medical and non-medical uses thereof.

Highly structured porous silica materials and biological uses thereof

There is herein provided a compound of formula I (I) or a pharmaceutically acceptable salt thereof, wherein the ring comprising Qto Q, R, m, Xand ring A have meanings as provided in the description.

Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia

There is herein provided a compound of formula (I).

Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia

A porous silica material for use as a pharmaceutical or dietary active ingredient having pores in the mesoscale range (2-50 nm), wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.

Porous silica material for use as a pharmaceutical or dietary active ingredient

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Qto Q, and the groups R, Rand R, have meanings as provided in the description.

Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R, R, R, Rand n have meanings as provided in the description.

Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia

There is herein provided a compound of formula (I). 

The present invention relates to an electric drive system for a bike comprising a portable electric friction drive device and a bike bracket. A first drive device attachment point is located at a rear part of the friction drive device. A second drive device attachment point is located between the front part of the friction drive device and the rear part of the friction drive device. An inclination control arrangement is configured to control the inclination of the imaginary line between the second drive device attachment point and a contact point of the drive wheel by adjusting the tilt of the friction drive device over the second drive device attachment point. The bike has at least one wheel, comprising the electric drive system, wherein the drive wheel is arranged to be contactable to the tire of said wheel at said contact point.

Electric friction drive device and electric drive system

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R, ring A, m and n have meanings as provided in the description. 

Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia

A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, said method comprising bringing a compound into contact with at least one population of cells, comprising cells that express mTOR and Akt and that are capable of activating mTORC2 and Akt; determining mTORC2 activity and Akt activity in cells brought into contact with the compound, and identifying the candidate compound based on the determined mTORC2 activity and Akt activity. A kit for use in such a method of. A compound for use in a method of treatment of a condition involving dysregulation of metabolism in a mammal, and a method of treatment of such a condition.

Screening method, a kit, a method of treatment and a compound for use in a method of treatement

A method to identify a candidate compound for use in the treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal, by identifying a candidate compound that causes an increase in translocation of GLUT without causing an increase in the production of cAMP. A kit for use in such a method. A method of treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal and a compound for use in such a method.

Screening method, a kit, a method of treatment and a compound for use in a method of treatment

A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, by bringing a compound into contact with cells that express a GPCR and that further express a GRK, determining whether the contacting causes a response of the GRK in cells brought into contact with the compound, determining whether the contacting causes a response of a classical secondary messenger in cells brought into contact with the compound; and identifying the candidate compound based on the determined GRK response and response of a classical secondary messenger in the cells. A kit for use in the method. A compound for use in the treatment of a condition involving dysregulation of metabolism in a mammal and a method of treatment of such a condition.

Growing community of inventors

Vaxholm, Sweden

Tore Bengtsson